Alzheimer's Drug Discovery Foundation’s Post

🔬 Join Akoya Biosciences, Inc. for an in-depth webinar on #immunofluorescence-based biomarker analysis, focusing on critical considerations for developing companion diagnostics. Discover the latest advancements in examining biomarker expression and tumor microenvironment heterogeneity using high-throughput technologies. The discussion will cover how multiplex fluorescence immunohistochemistry and image data analysis are uncovering spatial relationships between biomarkers, offering valuable insights into patient responses to immune checkpoint inhibitors, ADCs, and DDR therapies. Key Topics: 🔹 Essential strategies for developing companion diagnostics 🔹 Avoiding common pitfalls in multiplex immunofluorescence and multispectral imaging 🔹 Fully leveraging these technologies in clinical settings 👉 REGISTER HERE: https://buff.ly/4bJHSCD Expert speakers: Pascal Bamford Mark Landers #ClinicalResearch #Biomarkers #ClinicalData #CompanionDiagnostics #CDx #LaboratoryTechnology #MultispectralImaging #MultiplexImmunofluorescence

The application of artificial intelligence to the analysis of more than 150,000 specimens in Predictive Oncology’s on-demand biobank of live-cell tumor samples enables drug discovery and development partners to capture the heterogeneity of patient response profiles well in advance of clinical trials and to significantly increase the probability of technical success. Click here to learn more about how our proprietary Al-driven platform leverages our world-class biobank to accurately model and predict tumor-drug response, biomarker discovery, and patient stratification: https://lnkd.in/e2xBbHM2 #OncologyResearch #DrugDiscovery #Biobanking #PredictiveOncology #CancerResearch #BiomarkerDiscovery #PatientHeterogeneity #PrecisionMedicine

Advancing Spatial Biology to the Clinic: The Power of Multiplex #Immunofluorescence-based Biomarkers for Companion Diagnostics Webinar: Monday, June 10, 2024 | 2pm EDT / 11am PDT Learn about immunofluorescence-based biomarker analysis with key considerations for developing a companion diagnostic. Register today! #researchmatters #spatialbiology

This week I was delighted to attend the 7th Annual Targeted Protein Degradation (TPD) Summit in Boston where I spoke about the exciting R&D work underway at Astellas to bring innovative #TPD therapies to patients. In my presentation, I shared: 1.     Astellas’ long-term innovation strategy in TPD, which combines our oncology experience and proprietary expertise in KRAS mutant inhibitors with protein degrader capabilities, AI and robotics. 2.     The difference between inhibitors and degraders, and why we see such potential in degraders for addressing previously “undruggable” targets. 3.     Highlights from our work to build our TPD drug discovery platform and accelerate our lead asset in Phase 1 study for the treatment of solid tumors harboring KRAS G12D mutations. There is still much to learn, including the challenges associated with the unique properties of heterobifunctional degraders, PK/PD/efficacy correlations, and resistance mechanisms. However I am more encouraged than ever that, as a field, we will continue to make significant progress. I always enjoy sharing what we’ve discovered in order to expand our collective understanding and bring this promising modality to patients as soon as possible. #ScienceFirstForPatients #ChangingTomorrow

The application of artificial intelligence to the analysis of more than 150,000 specimens in Predictive Oncology’s on-demand biobank of live-cell tumor samples enables drug discovery and development partners to capture the heterogeneity of patient response profiles well in advance of clinical trials and to significantly increase the probability of technical success. Click here to learn more about how our proprietary Al-driven platform leverages our world-class biobank to accurately model and predict tumor-drug response, biomarker discovery, and patient stratification: https://lnkd.in/e2xBbHM2 #OncologyResearch #DrugDiscovery #Biobanking #PredictiveOncology #CancerResearch #BiomarkerDiscovery #PatientHeterogeneity #PrecisionMedicine

In a recent Q&A, Dr. Michelle Ting-Lin, Medical Director of Clinical Development at Tempus, provides insights into the science behind the Immune Profile Score (IPS), a novel biomarker designed to enhance the identification of patients who may benefit from immune checkpoint inhibitor (ICI) therapies. Read here: https://tempus.co/4i9EftN

The dynamic needs of your preclinical and translational studies require innovative technologies grounded in science, driven by data. Our end-to-end services use the most advanced analysis and generate comprehensive data, utilizing machine intelligence to help you make better-informed decisions. ✅OrganoidXploreᵀᴹ is our large-scale organoid panel screening platform providing robust, reproducible, and clinically relevant results. ✅SynAI is our AI-driven platform designed to predict the synergistic effects of cancer drug combinations, trained with over 1.2 million in vitro tests. ✅Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies, with seamless delivery.  ✅We provide certified CRO services using NanoString's GeoMx® platform to efficiently address tissue diversity and intricate micro-environments. Learn more➡️ https://hubs.la/Q02WPT0L0

We're thrilled to share our new research collaboration on the critical role of TEAD transcription factors in the Hippo-YAP/TAZ pathway. This project was recently presented at EORTC-NCI-AACR Symposium in Barcelona: https://lnkd.in/g9Ut5rsM Key Highlights:  - VT3989: A promising TEAD inhibitor that disrupts YAP/TAZ-TEAD interaction, showing potential to selectively block NF2-deficient mesothelioma proliferation.  - Clinical Insights: Early phase 1 trial results (NCT04665206) reveal promising partial responses in mesothelioma patients, regardless of NF2 mutation status.  - Innovative Biomarkers: Discovery's duplex IHC assay showcases a high specificity for Merlin and YAP protein expression, offering new avenues for patient stratification and therapy optimization. Check out the poster for a deep dive into these findings and their implications for future treatments. #CancerResearch #Mesothelioma #Biomarkers 

Advancing the Future of Healthcare Through Targeted Protein Degradation At SK Life Science Labs, we are steadfast in our belief that targeted protein degradation (TPD) will redefine the landscape of oncology and immunology. We are committed to pushing the boundaries of what's possible in TPD, expanding the range of disease targets we can effectively address. Our focus on innovation and accessibility drives us to make a profound impact on human health. Curious about how we're turning this vision into reality? Dive deeper into our journey and explore more about our groundbreaking work: https://lnkd.in/e__DVG7P #TPD #Oncology #Immunology #HealthcareInnovation #Biotech #CancerResearch

💡 Catch us at LMCE 2024 (Laboratory Medicine Congress & Exhibition 2024)! Bertis is excited to attend LMCE 2024, where experts in laboratory medicine gather amid the rapid advancements in the in vitro diagnostics industry to drive innovation and improve public health. At LMCE, we’ll showcase the technology and expertise that enabled us to commercialize MASTOCHECK, the world’s first proteomics-based early diagnostic blood test for breast cancer, and how we are expanding these innovations to develop solutions for pancreatic, ovarian, and other cancers. You’ll also have the opportunity to learn more about PASS (Pan-omics Analysis Service & Solution), our proteomics-based analytical service that helps biomarker discovery, drug R&D, and production. Come by our booth to see how Bertis is applying proteomics technology to revolutionize diagnostics! ✅ Find out more about Bertis: https://lnkd.in/gqJb9zUW #Bertis #LMCE #earlydiagnosis #proteomics #protein #biotech #biotechnology #PASS